Drug intelligence / Profile preview

HumaMAX

Development stage
Unknown
Lead developer
MOA Life Plus
Modality
Peptides
Administration
Oral
01

Overview

HumaMAX is a functional food ingredient platform developed by MOA Life Plus (formerly BLS Co., Ltd.) that utilizes high-molecular-weight poly-gamma-glutamic acid (γ-PGA). γ-PGA is a naturally occurring, water-soluble biopolymer produced through the fermentation of *Bacillus subtilis*. The HumaMAX platform has achieved significant regulatory milestones, including individual approval from the Korean Ministry of Food and Drug Safety (MFDS) as a functional raw material for immune enhancement and recognition as a New Dietary Ingredient (NDI) by the US FDA. It is primarily marketed for its ability to stimulate natural killer (NK) cell activity and modulate the immune response. Beyond its approved use for immune support, MOA Life Plus is investigating the HumaMAX platform for additional applications in gut health, stomach health, and the reduction of body fat, with these programs currently in preclinical development.

Brand names
HumaMAX
Other names
poly-gamma-glutamic acidgamma-PGAγ-PGApolyglutamic acid

Beyond the preview

Go deeper on HumaMAX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HumaMAX.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call